A Prospective Study of Daily Adaptive Radiotherapy to Better Organ-at-Risk Doses in Head and Neck Cancer
Status:
Not yet recruiting
Trial end date:
2023-12-15
Target enrollment:
Participant gender:
Summary
Varian Medical Systems has recently deployed a completely novel radiation treatment system
called EthosTM, a first-of-its-kind system that allows for daily adapative radiotherapy
(DART), such that the treatment for that day can be created on-the-fly based on the patient's
current positioning and anatomy. This system is commercially-available and FDA-approved, and
UTSW Radiation Oncology has installed two such units. The ability to adjust the dose delivery
every day means both that adaptive therapy is possible with every fraction and that the PTV
margin can be dramatically reduced/eliminated, since investigators are treating for that
day's patient setup. Investigators are therefore proposing a randomized trial using DART with
near marginless (ML) setup margins (a 1 mm margin will be retained for intrafractional
motion).